ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$27.29
−0.58%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$27.33
From 52W high−10.73%
Volume5.48M
Market cap$4.70B
P/E (TTM)12.1x
P/S (TTM)4.1x
Div yield—
Key dataSep 18, 2026
Open
$27.33
From 52W high
−10.73%
Volume
5.48M
Market cap
$4.70B
ValuationView details →
P/E (Fwd)
30.9x
EV/EBITDA
32.9x
P/E (TTM)
12.1x
RSI (14)
41.3
MomentumView details →
1D Return
−0.58%
YTD Return
+0.92%
SummaryUpdated Jun 1, 2026
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a San Diego-based biopharmaceutical company founded in 1993 that specializes in developing and commercializing treatments for central nervous system disorders. The company has evolved from a research-focused organization into a commercial-stage enterprise with two marketed products addressing rare neurological conditions. ACADIA went public in 2004 and has built its business around addressing unmet medical needs in neuropsychiatric and rare disease markets, with a particular focus on conditions affecting vulnerable patient populations including those with Parkinson's disease, Rett syndrome, and other neurological disorders.
Similar companies
Latest newsMore news →
The European Commission granted marketing authorization to Acadia Pharmaceuticals for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union, for adults and pediatric patients aged five years and older.27d agoACADIA Pharmaceuticals outlined commercial expansion plans for its marketed therapies DAYBUE and NUPLAZID during a Canaccord Genuity-hosted discussion.39d agoAcadia Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026, with total revenue growing 17% year-over-year on an adjusted basis.47d ago